title: Melatonin inhibits vasospastic action of oxidized low-density lipoprotein in human umbilical arteries.
abstract: We evaluated the antioxidant property of melatonin in countering the vasospastic effect of oxidized low-density lipoprotein (ox-LDL), which has been reported to be the most important risk factor for atherosclerosis and also may be linked to preeclampsia. Helical sections of umbilical arteries were obtained from human placentas at elective cesarean deliveries between 37 and 39 weeks of gestation. Changes in maximal tension induced by potassium chloride were measured in arterial sections with intact endothelium. ox-LDL (200 or 300 microg protein/mL) increased vascular tension by 15.6 +/- 2.3 or 31.9 +/- 4.0%, respectively. In contrast, native LDL only slightly increased vascular tension (2.7 +/- 1.0% for 200 microg protein/mL and 6.0 +/- 1.7% for 300 microg protein/mL). Pretreatment with L-N(G)-monomethyl-arginine (2 x 10(-4) M) significantly reduced the vasospastic effect of ox-LDL, as did pretreatment with mannitol (30 mM). Melatonin (10 microM) significantly reduced the vasospastic effect of ox-LDL. These findings suggest that ox-LDL potentiates vascular tension in the human umbilical artery, possibly by suppressing endothelial synthesis of nitric oxide. Melatonin significantly suppressed the vasospastic effect of ox-LDL, probably because it scavenges hydroxyl radical arising from ox-LDL.
authors.affiliation: Department of Obstetrics and Gynecology, Kochi Medical School, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Okatani
authors.forename: A
authors.initials: A
authors.lastname: Wakatsuki
authors.forename: K
authors.initials: K
authors.lastname: Watanabe
authors.forename: N
authors.initials: N
authors.lastname: Ikenoue
authors.forename: T
authors.initials: T
authors.lastname: Fukaya
mesh_terms: D000975:Antioxidants / Q000378:metabolism* / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004791:Enzyme Inhibitors / Q000494:pharmacology; D006801:Humans; D066298:In Vitro Techniques; D007537:Isometric Contraction / Q000187:drug effects / Q000502:physiology; D008077:Lipoproteins, LDL / Q000378:metabolism* / Q000494:pharmacology; D008353:Mannitol / Q000494:pharmacology; D008550:Melatonin / Q000378:metabolism* / Q000494:pharmacology; D010920:Placenta / Q000098:blood supply; D011189:Potassium Chloride / Q000494:pharmacology; D014469:Umbilical Arteries / Q000187:drug effects / Q000378:metabolism*; D014661:Vasoconstriction / Q000187:drug effects / Q000502:physiology*; D019323:omega-N-Methylarginine / Q000494:pharmacology
chemical_list: D000975:Antioxidants; D004791:Enzyme Inhibitors; D008077:Lipoproteins, LDL; C099252:oxidized low density lipoprotein; D019323:omega-N-Methylarginine; D008353:Mannitol; D011189:Potassium Chloride; D008550:Melatonin